TSVT — 2Seventy Bio Income Statement
0.000.00%
- $265.62m
- $95.24m
- $37.86m
- 42
- 27
- 80
- 48
Annual income statement for 2Seventy Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 248 | 54.5 | 91.5 | 100 | 37.9 |
| Cost of Revenue | |||||
| Gross Profit | 243 | 52 | 74.9 | 83.5 | 19.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 386 | 368 | 355 | 338 | 153 |
| Operating Profit | -138 | -314 | -263 | -238 | -115 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -120 | -292 | -254 | -218 | -57.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -120 | -292 | -254 | -218 | -57.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -120 | -292 | -254 | -218 | -57.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -120 | -292 | -254 | -218 | -57.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.14 | -12 | -6.86 | -4 | -1.6 |
| Dividends per Share |